KEY TAKEAWAY POINTS

The evolution of surgical glaucoma treatment has led to the development of procedures attempting to achieve better efficacy, but having variable complication profiles

MIGS devices have the capacity to provide efficacy and reduce complications with rapid patient recovery

The HYDRUS Microstent has a Tri-Modal^® mechanism of action that bypasses the trabecular meshwork, scaffolds Schlemm’s canal, and spans approximately 90° ensuring access to collector channels in the nasal region

The pivotal clinical data demonstrate that combining the HYDRUS Microstent with cataract surgery provides a durable decrease in IOP in adults with mild to moderate primary open-angle glaucoma with a concurrent decrease in medication dependence